14 February 2025 in Advanced Science
Macrophages are crucial drivers of innate immunity. Reprogramming macrophages to a restorative phenotype in cancer or autoimmune diseases can stop their cancer‐promoting activity or trigger anti‐inflammatory immunity. Glycans have emerged as key components for immunity as they are involved in many pathophysiological disorders. Previous studies have demonstrated that supraphysiological amounts of mannose (Man) or sialic acid (Sia) can inhibit tumor growth and stimulate differentiation of regulatory T cells. Man is known to affect glucose metabolism in glycolysis by competing for the same intracellular transporters and affecting macrophage polarization, whereas Sia alters macrophage differentiation via signaling through Siglec‐1. Herein, this work describes a macrophage targeting platform using gold nanoparticles (GNPs) functionalized with Man and Sia monosaccharides which exhibit high liver tropism. A single dose of glyco‐GNPs can convert macrophages to a restorative phenotype in two completely different immune environments. Man promotes tumor‐associated macrophages toward an antitumorigenic activity in a MC38 liver colorectal cancer model by secretion of TNF‐α, IL ‐1β, and IL ‐6 in the tumor microenvironment. However, in a proinflammatory environment, as observed in a mouse model of autoimmune disease, primary biliary cholangitis, Man impairs the production of TNF‐α, IL‐1β, Arg1, and IL‐6 cytokines. The results probe the dual role of Man in macrophage repolarization in response to the immune system. This study is a proof‐of‐concept that demonstrates that nanomedicine using specific glycans designed to target other immune cells such as myeloid cells, are a promising strategy not only against cancer but also against other pathologies such as autoimmune diseases.
1 July 2024 in International Journal of Pharmaceutics
20 April 2026 in Nanoscale Advances
This review navigates the Nanoverse , an expanding dimension that connects emerging nanoscale materials with medicine, biosensing, and safety, highlighting how innovation, regulation, and ethics converge to guide nanotechnology for a better society.
16 November 2023 in Biomaterials
Nanodecoy systems based on analogues of viral cellular receptors assembled onto fluid lipid-based membranes of nano/extravescicles are potential new tools to complement classic therapeutic or preventive antiviral approaches. The need for lipid-based membranes for transmembrane receptor anchorage may pose technical challenges along industrial translation, calling for alternative geometries for receptor multimerization. Here we developed a semisynthetic self-assembling SARS-CoV-2 nanodecoy by multimerizing the biotin labelled virus cell receptor -ACE2- ectodomain onto a poly-avidin nanoparticle (NP) based on the Avidin-Nucleic-Acid-NanoASsembly-ANANAS. The ability of the assembly to prevent SARS-CoV-2 infection in human lung cells and the affinity of the ACE2:viral receptor-binding domain (RBD) interaction were measured at different ACE2:NP ratios. At ACE2:NP = 30, 90 % SARS-CoV-2 infection inhibition at ACE2 nanomolar concentration was registered on both Wuhan and Omicron variants, with ten-fold higher potency than the monomeric protein. Lower and higher ACE2 densities were less efficient suggesting that functional recognition between multi-ligand NPs and multi-receptor virus surfaces requires optimal geometrical relationships. In vivo studies in mice showed that the biodistribution and safety profiles of the nanodecoy are potentially suitable for preventing viral infection upon nasal instillation. Viral receptor multimerization using ANANAS is a convenient process which, in principle, could be rapidly adapted to counteract also other viral infections.
22 July 2026 in Biomedicine & Pharmacotherapy
Primary biliary cholangitis (PBC) is the most common life-long autoimmune liver disease arising from a biliary epithelial activation to a complex evolving cascade of immune-mediated injury, leading to inflammation and fibrosis and ultimately cirrhosis and liver failure. Ursodeoxycholic acid (UDCA) remains the only first-line treatment, despite being ineffective in approximately 40% of patients. Inadequate response to UDCA has been associated with increased death risk or need for liver transplantation. Starting from these premises, novel or repurposed drugs are currently needed. Immunosuppressive therapies, such as corticosteroids, remain controversial, primarily due to safety concerns related to off-target effects and limited evidence of enhanced efficacy. Nanoparticles are known to accumulate in the liver. Among them, Avidin-Nucleic-Acids-Nano-ASsemblies (ANANAS) have emerged as promising drug carriers thanks to their multi-functionality and convenient tunability, biodegradability, biocompatibility and scalable manufacturing. Despite the availability of numerous PBC models, none replicate key features of human disease to the degree observed in ARE Del-/- mice. Focusing on this model, ANANAS loaded with acid-releasable dexamethasone (ANANAS-Hz-Dex-M) were parenterally administered to evaluate distribution, pharmacokinetics, and therapeutic efficacy. The single treatment demonstrated selective liver tropism with an exclusive steroid release, and interaction with resident macrophages. Multiple administrations significantly reduced hepatic fibrosis. In vitro, isolated Kupffer cells from ARE Del-/- internalize the nanoassembly, with a reduction of the inflammatory profile. Our findings delineate ANANAS-Hz-Dex-M as a tool with the potential to guide resident macrophage plasticity and ameliorate disease course.